News
Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...
MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...
Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy. On June 24, Piper Sandler reaffirmed its ...
Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...
The healthcare sector, represented by the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), underperformed the broader ...
Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...
5d
Woman's World on MSNNew GLP-1 Called MariTide Shows 20% Weight Loss-Without a PlateauDavid Petrus IbarsIn the same way weight varies from person to person, so do the best weight loss strategies. While some ...
Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...
6d
Investor's Business Daily on MSNCan Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.
Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...
They also have strong dividend track records. Apple and Amgen have lagged the market over the trailing-12-month period, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results